{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:37:26Z","timestamp":1787319446705,"version":"build-2736575974"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.amjms.2025.10.007","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:07:03Z","timestamp":1760796423000},"page":"170-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Infectious complications of chimeric antigen receptor T cell therapy and bispecific antibodies \u2013 A review"],"prefix":"10.1016","volume":"371","author":[{"given":"Bradley","family":"Dye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gromer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibi","family":"Maryam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0001","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"24","key":"10.1016\/j.amjms.2025.10.007_bib0002","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.007_bib0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00005-020-00599-x","article-title":"The application of CAR-T cells in haematological malignancies","volume":"68","author":"Skorka","year":"2020","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.007_bib0004","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12272-019-01136-x","article-title":"Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives","volume":"42","author":"Lee","year":"2019","journal-title":"Arch Pharm Res"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.007_bib0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.007_bib0006","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.007_bib0007","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(20)30376-8","article-title":"Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?","volume":"8","author":"Gudiol","year":"2021","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.amjms.2025.10.007_bib0008","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.007_bib0009","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/phar.1900","article-title":"Chimeric antigen receptor T cells in hematologic malignancies","volume":"37","author":"Shank","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.amjms.2025.10.007_bib0011","article-title":"How I treat adverse effects of CAR-T cell therapy","volume":"4","author":"Yanez","year":"2020","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.007_bib0012","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.007_bib0013","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"10.1016\/j.amjms.2025.10.007_bib0014","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/14787210.2022.2128762","article-title":"Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis","volume":"20","author":"Telli Dizman","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.amjms.2025.10.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104134","article-title":"Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis","volume":"192","author":"Reynolds","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.007_bib0016","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cmi.2023.05.011","article-title":"Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: a systematic scoping review and narrative synthesis","volume":"29","author":"Reynolds","year":"2023","journal-title":"Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.007_bib0017","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0018","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.007_bib0019","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13613-024-01247-9","article-title":"Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort","volume":"14","author":"Le Cacheux","year":"2024","journal-title":"Ann Intensive Care"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.007_bib0021","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0022","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","volume":"108","author":"Beyar-Katz","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.amjms.2025.10.007_bib0023","first-page":"1","article-title":"Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy","author":"Bindal","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.007_bib0024","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14202","article-title":"Infections in children following chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia","volume":"25","author":"Diamond","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.007_bib0025","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ejh.14122","article-title":"Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy","volume":"112","author":"Garcia-Pouton","year":"2024","journal-title":"Eur J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.amjms.2025.10.007_bib0026","article-title":"Infectious complications of car T-cell therapy: A longitudinal risk model","volume":"25","author":"Czapka","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.007_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14376","article-title":"Infections following chimeric antigen receptor T cell therapy: 2018-2022","volume":"26","author":"Keri","year":"2024","journal-title":"Transpl Infect Dis"},{"issue":"24","key":"10.1016\/j.amjms.2025.10.007_bib0028","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.007_bib0029","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.amjms.2025.10.007_bib0030","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.007_bib0031","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ejh.14207","article-title":"Patients with aggressive B-cell lymphoma receiving CAR T-cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis","volume":"113","author":"Pernas","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.amjms.2025.10.007_bib0032","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.amjms.2025.10.007_bib0033","article-title":"Infectious complications among CD19 CAR-T cell therapy recipients: A single-center experience","volume":"25","author":"Walker","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.007_bib0034","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","article-title":"Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells","volume":"62","author":"Wittmann Dayagi","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.007_bib0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.007_bib0036","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.007_bib0037","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, Adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.amjms.2025.10.007_bib0038","article-title":"Case Report: active tuberculosis infection in CAR T-cell recipients post CAR T-cell therapy: a retrospective case series","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.007_bib0039","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/RLU.0000000000004655","article-title":"New onset of tuberculosis complicating FDG PET\/CT evaluation in patient with recent chimeric antigen receptor T-cell therapy","volume":"48","author":"Wang","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.007_bib0040","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41409-020-0808-6","article-title":"Fatal mycobacterium abscessus in a recipient of axicabtagene ciloleucel CAR-T: beware of T cells","volume":"55","author":"Kase","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.007_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242513","article-title":"Lethal hyperammonemia in a CAR-T cell recipient due to ureaplasma pneumonia: a case report of a unique severe complication","volume":"14","author":"Tawfik","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.007_bib0042","doi-asserted-by":"crossref","first-page":"304.e1","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with Multiple myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.007_bib0043","doi-asserted-by":"crossref","first-page":"31","DOI":"10.46989\/001c.115932","article-title":"Managing infection complications in the setting of chimeric antigen receptor T cell (CAR-T) therapy","volume":"6","author":"Ahmed","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"12","key":"10.1016\/j.amjms.2025.10.007_bib0044","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","article-title":"State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.007_bib0045","first-page":"955","article-title":"Best practice considerations by The American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell Therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.amjms.2025.10.007_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1404351","article-title":"Late events after anti-CD19 CAR T-cell therapy for relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"14","author":"Cordeiro","year":"2024","journal-title":"Front Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.amjms.2025.10.007_bib0047","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"30","key":"10.1016\/j.amjms.2025.10.007_bib0048","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0049","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/s12967-024-05308-2","article-title":"Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies","volume":"22","author":"Pu","year":"2024","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.007_bib0050","first-page":"ofae398","article-title":"Chimeric antigen receptor T-cell postinfusion fever: infection profile","volume":"11","author":"Peyrony","year":"2024","journal-title":"Clin Parameters Biomark Trends Assist Antibiot Steward Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0051","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.007_bib0052","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1002\/cam4.5665","article-title":"Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients","volume":"12","author":"Powell","year":"2023","journal-title":"Cancer Med"},{"issue":"24","key":"10.1016\/j.amjms.2025.10.007_bib0053","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.007_bib0054","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.amjms.2025.10.007_bib0055","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0056","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.007_bib0057","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.amjms.2025.10.007_bib0058","article-title":"Development of ALL-Hematotox (ALL-HT): predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","author":"Nair","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.amjms.2025.10.007_bib0059","doi-asserted-by":"crossref","first-page":"708.e1","DOI":"10.1016\/j.jtct.2023.08.013","article-title":"Early antibiotic deescalation and discontinuation in patients with Febrile neutropenia after cellular therapy: A single-center prospective unblinded randomized trial","volume":"29","author":"Ram","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.007_bib0060","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14236","article-title":"Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies","volume":"26","author":"Stohs","year":"2024","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.007_bib0061","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13175","article-title":"Penicillin allergy skin testing as an antibiotic stewardship intervention reduces alternative antibiotic exposures in hematopoietic stem cell transplant recipients","volume":"21","author":"Modi","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"10.1016\/j.amjms.2025.10.007_bib0062","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.007_bib0063","doi-asserted-by":"crossref","first-page":"277.e1","DOI":"10.1016\/j.jtct.2022.08.011","article-title":"Pneumococcal conjugate vaccine does not induce humoral response when administrated within the six months after CD19 CAR T-cell therapy","volume":"29","author":"Lee","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0064","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.amjms.2025.10.007_bib0065","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood.2021014989","article-title":"Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy","volume":"139","author":"Terpos","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.007_bib0066","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.cmi.2024.11.008","article-title":"Timeline and outcomes of viral and fungal infections after chimeric antigen receptor T-cell therapy: a large database analysis","volume":"31","author":"Sassine","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.amjms.2025.10.007_bib0067","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.007_bib0068","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0069","article-title":"Outcomes and management of the SARS-CoV2 omicron variant in recipients of hematopoietic","volume":"30","author":"Infante","year":"2024","journal-title":"Cell Transplant Chimeric Antigen Recept T Cell Ther Transpl Cell Ther"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.007_bib0070","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1093\/cid\/ciab072","article-title":"Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute Respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: A case study","volume":"73","author":"Hensley","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"26","key":"10.1016\/j.amjms.2025.10.007_bib0071","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer","volume":"383","author":"Aydillo","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.007_bib0072","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ajh.26209","article-title":"Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy","volume":"96","author":"Dulery","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.007_bib0073","doi-asserted-by":"crossref","first-page":"ofad166","DOI":"10.1093\/ofid\/ofad166","article-title":"Respiratory viral infections in recipients of cellular therapies: A review of incidence, outcomes, treatment, and prevention","volume":"10","author":"Wilson Dib","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"22","key":"10.1016\/j.amjms.2025.10.007_bib0074","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1182\/bloodadvances.2024012762","article-title":"Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells","volume":"8","author":"Kocoglu","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cmi.2024.06.020","article-title":"Advances and prospect in herpesviruses infections after haematopoietic cell transplantation: closer to the finish line?","volume":"31","author":"Sassine","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0076","doi-asserted-by":"crossref","DOI":"10.3390\/v17010133","article-title":"Herpesvirus infections after chimeric antigen receptor T-cell therapy and bispecific antibodies: A review","volume":"17","author":"Sassine","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.amjms.2025.10.007_bib0077","doi-asserted-by":"crossref","unstructured":"Khawaja F, Sassine J, Handley G, et al. Herpesviruses infections in CAR T cell recipients. 2022 tandem meetings - transplantation & cellular therapy meetings of ASTCT and CIBMTR. Tandem meetings; 2022.","DOI":"10.1016\/S2666-6367(22)00649-2"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.007_bib0078","doi-asserted-by":"crossref","first-page":"ofae422","DOI":"10.1093\/ofid\/ofae422","article-title":"Cytomegaloviral infections in recipients of chimeric antigen receptor T-cell therapy: an observational study with focus on oncologic outcomes","volume":"11","author":"Khawaja","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.007_bib0079","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"16","key":"10.1016\/j.amjms.2025.10.007_bib0080","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.007_bib0081","article-title":"Invasive fungal infections after anti-CD19 chimeric antigen receptor-modified T-cell therapy: State of the evidence and future directions","volume":"7","author":"Garner","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.007_bib0082","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0083","first-page":"36","article-title":"Shift from widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T cell therapy: results from a large retrospective cohort","volume":"31","author":"Melica","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.007_bib0084","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/ciac882","article-title":"The geographic distribution of dimorphic mycoses in the United States for the modern era","volume":"76","author":"Mazi","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.007_bib0085","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/tid.12372","article-title":"Diagnosis, treatment, and outcomes of coccidioidomycosis in allogeneic stem cell transplantation","volume":"17","author":"Mendoza","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.amjms.2025.10.007_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.amjms.2025.10.007_bib0087","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","article-title":"T-cell-recruiting antibodies in B-cell malignancies","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.007_bib0088","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.19668","article-title":"Mitigating infection risks: the promise and challenge of bispecific antibodies in haematological malignancies","volume":"205","author":"Rafei","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.007_bib0089","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.amjms.2025.10.007_bib0090","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.amjms.2025.10.007_bib0091","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.007_bib0092","doi-asserted-by":"crossref","first-page":"e7048","DOI":"10.1002\/cam4.7048","article-title":"Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: real-world evidence from Sweden","volume":"13","author":"Uttervall","year":"2024","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.007_bib0093","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol"},{"issue":"13","key":"10.1016\/j.amjms.2025.10.007_bib0094","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.amjms.2025.10.007_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107544","article-title":"Multiple myeloma and infections in the era of novel treatment modalities","volume":"143","author":"Akhmedov","year":"2024","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.007_bib0096","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s10238-023-01000-9","article-title":"Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia","volume":"23","author":"Quattrone","year":"2023","journal-title":"Clin Exp Med"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.007_bib0097","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.007_bib0098","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0099","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.007_bib0100","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0101","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.007_bib0102","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.007_bib0103","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.amjms.2025.10.007_bib0104","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.amjms.2025.10.007_bib0105","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.007_bib0106","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"24","key":"10.1016\/j.amjms.2025.10.007_bib0107","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.amjms.2025.10.007_bib0108","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.007_bib0109","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925012492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925012492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:53:33Z","timestamp":1769090013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962925012492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0002962925012492"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2025.10.007","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infectious complications of chimeric antigen receptor T cell therapy and bispecific antibodies \u2013 A review","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2025.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}